ReviewJournal of neuro-oncology2001
The role of p53 in human cancer.
Review in Journal of neuro-oncology, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 52 citations in OpenAlex.
- Gene Therapy for Lung Cancer.Critical reviews in oncogenesis · 2016Review
- Duplex Detection of TP53 Arg72Pro and 16 bp Del/Ins Polymorphisms by a Simple Optimized PCR-RFLP Method.North American journal of medical sciences · 2012Article
- Genotyping of BRCA1, BRCA2, p53, CDKN2A, MLH1 and MSH2 genes in a male patient with secondary breast cancer.Radiology and oncology · 2011Article
- Constitutional haploinsufficiency of tumor suppressor genes in mentally retarded patients with microdeletions in 17p13.1.Cytogenetic and genome research · 2009Article
- The molecular genetics of adrenocortical carcinoma.Reviews in endocrine & metabolic disorders · 2007Review
- Malignant glioma: neuropathology and neurobiology.Wiener medizinische Wochenschrift (1946) · 2006Review
- Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89.The American journal of pathology · 2003Article
- Neurotoxicity of platinum compounds: comparison of the effects of cisplatin and oxaliplatin on the human neuroblastoma cell line SH-SY5Y.Journal of neuro-oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the two decades since its original discovery, p53 has found a singularly prominent place in our understanding of human cancer. Although the biochemistry of p53 has been worked out in some detail, our knowledge of the biologic consequences of p53 dysfunction is still quite rudimentary. Over the next several years, it will be important to determine how best to harness the complex properties of p53's ability to induce cellular growth arrest and cell death to generate novel, effective approaches to cancer therapy. Furthermore, a clearer appreciation of the direct interaction of epigenetic factors with p53 will lead to development of strategies to inhibit tumour initiation and progression. The next decade promises to offer exciting opportunities to apply our vast knowledge of this intriguing tumor suppressor to clinical advantage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.